期刊
JOURNAL OF HEPATOLOGY
卷 43, 期 1, 页码 78-84出版社
ELSEVIER
DOI: 10.1016/j.jhep.2005.02.025
关键词
HIV; hepatitis C; co-infection; fibrosis markers
资金
- AHRQ HHS [HS 07-809] Funding Source: Medline
- NCRR NIH HHS [M01-RR00052] Funding Source: Medline
- NIDA NIH HHS [DA-13806, DA-16065, DA-11602] Funding Source: Medline
Background/Aims: To examine if serum fibrosis biomarkers could accurately identify the stage of liver disease amongst hepatitis C (HCV) and HIV co-infected patients. Methods: One hundred and thirty seven HIV/HCV co-infected persons were randomly selected from the Johns Hopkins HIV Clinic cohort. Ninety five had complete testing for fibrosis markers in sera collected at the time of liver biopsy. Biopsies were scored according to Ishak modified histological activity index (F0 no fibrosis to F6 cirrhosis). Fibrosis was evaluated against alanine aminotransferase (ALT), aspartate aminotransferase (AST), AST to platelet ratio (APRI), albumin, total bilirubin, hyaluronic acid (HA) and YKL-40. Results: Sixty nine (73%) had no or minimal portal fibrosis (F0-2) and were compared with remaining subjects (F3-6). Fibrosis scores >= F3 were found 27 times more often in persons with HA levels > 86 ng/ml and 5.5 times more often in persons with HA levels 41-86 ng/ml. Less substantial associations were detected with levels of albumin < 3.5 g/dl (OR 4.85) and AST > 60 in (OR 5.91). All 35 subjects who had favorable results of HA, albumin, and AST had minimal fibrosis (F0-2). Conclusions: Amongst HIV/HCV co-infected patients, serum testing for HA, albumin, and AST (SHASTA Index) was able to accurately stage mild and advanced fibrosis. (c) 2005 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据